Phibro Animal Health Corporation Q4 2025 Earnings Recap

Strong demand in the Animal Health segment propelled Phibro Animal Health Corporation to a robust finish in fiscal 2025, with significant sales growth and operational leverage improvements.

Key Takeaways

• Q4 consolidated net sales rose 39% to $378.7 million, driven by a 53% increase in the Animal Health segment.
• Adjusted EBITDA for Q4 increased by 49%, highlighting effective cost management and operational efficiencies.
• The fiscal year concluded with total revenues of $1.296 billion, a 27% increase year-over-year, and adjusted EBITDA growth of 65%.
• Guidance for fiscal 2026 projects net sales between $1.425 billion and $1.475 billion, reflecting confidence in ongoing momentum.
• Continued success attributed to the integration of the MFA business and advancements from the Phibro Forward strategy.